Sanofi to Sell Controlling Stake in Opella to CD&R Amid Industry Shift

Sanofi's strategic decision to sell a controlling stake in Opella to Clayton Dubilier & Rice (CD&R) reflects its focused shift towards enhancing its core biopharmaceutical operations. This move aligns with a broader industry trend, where major pharmaceutical players like Novartis, Pfizer, and GSK are divesting consumer health divisions to concentrate on innovative medicines and vaccines. The sale, potentially valued at around 15 billion euros, will provide Sanofi with the financial resources needed to bolster its primary business, which already reported over 18 billion euros in sales in the first half of the year[1][2].